Anbio Biotechnology [NNNN] vs Becton, Dickinson [BDX] Detailed Stock Comparison

Anbio Biotechnology Ltd.

NASDAQ
Loading...

Becton, Dickinson and Company

NYSE
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: Anbio Biotechnology Ltd. wins in 7 metrics, Becton, Dickinson and Company wins in 9 metrics, with 1 ties. Becton, Dickinson and Company appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Anbio Biotechnology Ltd. Becton, Dickinson and Company Better
P/E Ratio (TTM) 181.00 25.40 Becton, Dickinson and Company
Price-to-Book Ratio 39.52 1.75 Becton, Dickinson and Company
Debt-to-Equity Ratio 0.00 77.28 Tie
PEG Ratio N/A 0.92 N/A
EV/EBITDA 223.68 10.49 Becton, Dickinson and Company
Profit Margin (TTM) 74.06% 8.01% Anbio Biotechnology Ltd.
Operating Margin (TTM) 59.09% 13.35% Anbio Biotechnology Ltd.
EBITDA Margin (TTM) 59.09% 13.35% Anbio Biotechnology Ltd.
Return on Equity 27.05% 6.96% Anbio Biotechnology Ltd.
Return on Assets (TTM) 14.66% 4.08% Anbio Biotechnology Ltd.
Free Cash Flow (TTM) $-6.74M $2.67B Becton, Dickinson and Company
Dividend Yield N/A 2.56% N/A
1-Year Return 80.02% 8.01% Anbio Biotechnology Ltd.
Price-to-Sales Ratio (TTM) 137.81 2.57 Becton, Dickinson and Company
Enterprise Value $1.18B $63.40B Becton, Dickinson and Company
EV/Revenue Ratio 136.44 2.89 Becton, Dickinson and Company
Gross Profit Margin (TTM) N/A 45.91% N/A
Revenue per Share (TTM) $0 $76 Becton, Dickinson and Company
Earnings per Share (Diluted) $0.15 $6.13 Becton, Dickinson and Company
Beta (Stock Volatility) N/A 0.35 N/A
Short % of Float 0.07% 3.78% Anbio Biotechnology Ltd.

Anbio Biotechnology Ltd. vs Becton, Dickinson and Company Stock Performance Analysis

Loading Price Chart...

NNNN
BDX

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Anbio Biotechnology Ltd.7.83%-2.38%-37.60%-22.96%-40.81%-42.98%
Becton, Dickinson and Company-0.49%-2.98%1.43%-9.20%-7.49%-5.04%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Anbio Biotechnology Ltd.80.02%170.19%170.19%170.19%170.19%170.19%
Becton, Dickinson and Company8.01%-28.08%-20.73%15.00%123.99%212.28%

Performance & Financial Health Analysis: Anbio Biotechnology Ltd. vs Becton, Dickinson and Company

MetricNNNNBDX
Market Information
Market Cap i$1.20B$56.10B
Market Cap CategorySmall capLarge cap
10 Day Avg. Volume i28,6212,759,250
90 Day Avg. Volume i30,9272,521,130
Last Close$16.81$145.52
52 Week Range$8.60 - $55.65$127.59 - $187.35
% from 52W High-69.79%-22.33%
All-Time High$55.65 (Jul 15, 2025)$287.32 (Jul 24, 2023)
% from All-Time High-69.79%-49.35%
Growth Metrics
Quarterly Revenue Growth0.74%0.02%
Quarterly Earnings GrowthN/A0.26%
Financial Health
Profit Margin (TTM) i0.74%0.08%
Operating Margin (TTM) i0.59%0.13%
Return on Equity (TTM) i0.27%0.07%
Debt to Equity (MRQ) i0.0077.28
Cash & Liquidity
Book Value per Share (MRQ)$0.69$88.79
Cash per Share (MRQ)$0.27$2.64
Operating Cash Flow (TTM) i$-6,739,075$3.39B
Levered Free Cash Flow (TTM) i$-9,605,703$3.11B
Dividends
Last 12-Month Dividend Yield iN/A2.56%
Last 12-Month Dividend iN/A$4.18

Valuation & Enterprise Metrics Analysis: Anbio Biotechnology Ltd. vs Becton, Dickinson and Company

MetricNNNN (Apr 24, 2026)BDX (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i181.0025.40
Forward P/E iN/A11.53
PEG Ratio iN/A0.92
Price to Sales (TTM) i137.812.57
Price to Book (MRQ) i39.521.75
Market Capitalization
Market Capitalization i$1.20B$56.10B
Enterprise Value i$1.18B$63.40B
Enterprise Value Metrics
Enterprise to Revenue i136.442.89
Enterprise to EBITDA i223.6810.49
Risk & Other Metrics
Beta iN/A0.35
Book Value per Share (MRQ) i$0.69$88.79

Financial Statements Comparison: Anbio Biotechnology Ltd. vs Becton, Dickinson and Company

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricNNNN (2025)BDX (2025)
Revenue/Sales i8.65M21.84B
Cost of Goods Sold i1.10M11.92B
COGS % of Revenue i12.8%54.6%
Gross Profit i7.54M9.93B
Gross Margin i87.2%45.4%
Research & Development i201,3051.27B
Operating Income (EBIT) i5.77M2.99B
Operating Margin i66.7%13.7%
EBITDA i5.27M5.42B
EBITDA Margin i61.0%24.8%
Pre-Tax Income i6.40M1.88B
Pre-Tax Income % of Revenue i74.1%8.6%
Income Tax i0203.00M
Income Tax % of Revenue i0.0%0.9%
Net Income (Profit) i6.40M1.68B
Profit Margin i74.1%7.7%

Balance Sheet & Liquidity Metrics

MetricNNNN (2025)BDX (2025)
Cash & Equivalents i7.77M641.00M
Total Current Assets i30.24M9.26B
Total Current Assets % of Revenue i349.8%42.4%
Total Current Liabilities i87,8368.31B
Total Current Liabilities % of Revenue i1.0%38.1%
Long-Term Debt iN/A17.62B
Long-Term Debt % of Revenue i0.0%80.7%
Total Shareholders Equity i30.16M25.39B
Retained Earnings i23.58M16.62B
Retained Earnings % of Revenue i272.7%76.1%
Property, Plant & Equipment iN/A0

Cash Flow Statement Comparison

MetricNNNN (2025)BDX (2025)
Operating Cash Flow i2.17M3.68B
Operating Cash Flow % of Revenue i25.1%16.9%
Capital Expenditures iN/AN/A
Free Cash Flow i-6.74M2.67B
FCF Margin i-77.9%12.2%
Debt Repayment iN/A-1.79B
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricNNNNBDX
Shares Short i30,5099.49M
Short Ratio i0.833.92
Short % of Float i0.07%3.78%
Shares Outstanding i43.89M284.74M
Float Shares i39.69M283.99M
% Held by Insiders i4.78%0.40%
% Held by Institutions i4.85%96.58%
% Held by Public i90.37%3.02%

Dividend Analysis & Yield Comparison: Anbio Biotechnology Ltd. vs Becton, Dickinson and Company

MetricNNNNBDX
Last 12-Month Dividend iN/A$4.18
Last 12-Month Dividend Yield iN/A2.56%
3-Year Avg Annual Dividend iN/A$3.96
3-Year Avg Dividend Yield iN/A0.58%
3-Year Total Dividends iN/A$11.88
Ex-Dividend DateN/AMar 10, 2026